Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Paolo Alberto Paciucci"'
Autor:
Deborah Lehrer, Christina Weltz, George Raptis, Rita Gurry, Ira J. Bleiweiss, Paolo Alberto Paciucci
Publikováno v:
Anti-Cancer Drugs. 13:791-795
Neo-adjuvant, dose-dense docetaxel, 100 mg/m(2) every 2 weeks x 4 cycles, was administered to 12 patients with locally advance breast cancer (LABC) (10 stage IIIa and three stage IIIb). Eligibility requirements included a PS 0-2, normal hepatic and r
Autor:
James F. Holland, Roger B. Davis, Janet Cuttner, Arlan J. Gottlieb, Paolo Alberto Paciucci, Orlando Martelo
Publikováno v:
American Journal of Hematology. 56:214-218
Mitoxantrone (M) is a synthetic aminoanthraquinone with anti-leukemic activity in patients with daunorubicin (D) resistant acute leukemia. The Cancer and Leukemia Group B (CALGB) has undertaken a limited access pilot study in which M, 12 mg/m 2 , ove
Autor:
Paolo Alberto Paciucci, R. Odchimar, P. A. Chahinian, J. S. Ryder, J. G. Bekesi, James F. Holland
Publikováno v:
American Journal of Clinical Oncology. 14:341-348
Twelve women and 7 men, median age 58 (range 17-74), with a diagnosis of non-small-cell lung cancer (11 patients), inflammatory breast cancer (5 patients), osteosarcoma (2 patients), and colon carcinoma (1 patient) were studied. Treatment consisted o
Publikováno v:
The American Journal of Medicine. 89:308-312
To elucidate some of the possible mechanisms that lead to interleukin-2 (IL2)-induced thrombocytopenia.We evaluated retrospectively the effects of immunotherapy with IL2 in 76 patients with disseminated cancer. The lymphokine was administered by cons
Autor:
Narayan Sundaresan, Kevin Kelligher, Ved Prakash Sachdev, Paolo Alberto Paciucci, James F. Holland, Laura Hough, Li-Teh Wu, Max Sung, Frank Moore
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13(9)
PURPOSE A retrospective study of the results of neoplastic cord compression was undertaken to determine the effectiveness of surgical treatment and to assess quality of life in patients undergoing extensive procedures with potential morbidity. PATIEN
Autor:
Pauli Puolakkainen, John Mandeli, Paolo Alberto Paciucci, Dan Twardzik, Mauro Moroni, Jane E. Ranchalis
Publikováno v:
Cancer investigation. 13(6)
Interleukin-2 (IL-2) is a lymphokine with pleiotropic activities on the immune system. When administered in vivo, besides inducing unrestricted tumor cytotoxicity, it is also responsible for the secondary release of other lymphokines, such as IL-1, T
Autor:
Jane E. Ranchalis, Leslie Oleksowicz, Paolo Alberto Paciucci, Pauli Puolakkainen, Daniel R. Twardzik
Publikováno v:
Growth Factors, Peptides and Receptors ISBN: 9780306444845
Interleukin-2 (IL-2), originally discovered in the supernatant of lectin or antigen-stimulated T-cell cultures1-2, possesses a panoply of immunologic effects such as induction of paracrine growth of antigen-stimulated T-lymphocytes and of non-MHC res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cb253dcd46828c865605e91033696ca
https://doi.org/10.1007/978-1-4615-2846-3_41
https://doi.org/10.1007/978-1-4615-2846-3_41
Autor:
Dina Zuckerman, Paolo Alberto Paciucci, Leslie Oleksowicz, James F. Holland, Anthony Colorito, Jacob H. Rand
Publikováno v:
Journal of immunotherapy : official journal of the Society for Biological Therapy. 10(5)
We recently reported that thrombocytopenia and bleeding are often limiting effects of immunotherapy with interleukin-2 (IL-2). In order to understand the mechanisms that lead to this unexpected clinical toxicity, we studied the effects of IL-2 on in
Autor:
Charles A. Schiffer, Paolo Alberto Paciucci, Roger B. Davis, Orlando Martelo, James F. Holland
Publikováno v:
American journal of clinical oncology. 13(6)
In an effort to search for new, synergistic and non-cross-resistant antileukemic regimens, the Cancer and Leukemia Group B (CALGB) investigated the activity and toxicity of mitoxantrone in combination with etoposide for the reinduction of patients wi
Publikováno v:
American journal of hematology. 35(1)
Based on in vitro evidence of time-dependent synergistic kill of HL-60 leukemia cells exposed to Ara-C and mitoxantrone, 44 patients with relapsed or refractory AML and 3 with blastic CML were treated with a timed sequence of both drugs. There were 2